摘要
Abstract
Objective To investigate androgen receptor (AR) expression in breast cancer tissues and its relationship with clinicopathological indicators and molecular subtypes. Methods Androgen receptor (AR), estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor-2 (HER2) and proliferating cell nuclear antigen Ki-67 expression were evaluated in 200 breast cancer cases by immunohistochemistry assays. Data including patients' age, menstrual status, tumor size, lymph node metastasis, pathology TNM (pTNM) stage and tumor histological grade and other clinical pathological indicators were analyzed. Results The positive rate of AR in breast cancer tissue was 88.5%. It was 67.9% in ER negative breast cancer versus 95.9% in ER positive breast cancer, and 68.4% in PR negative breast cancer versus 96.5% in PR positive breast cancer. AR expression was positively associated with ER and PR expression (P < 0.01, respectively). The positive rate of AR was 94.9% in grade Ⅰ and grade Ⅱ breast cancer, and 74.2% in grade Ⅲ . The lower the histological grade was, the higher the positive rate of AR expression was (P < 0.01). The positive rate of AR was 96.3% in Luminal A subtypes and 96% in Luminal B subtypes, and was 87.5% in HER2 positive subtypes, and 44% in triple negative breast cancer (TNBC), and there were significant differences in different molecular subtypes (P < 0.01). Subtypes of Luminal A, Luminal B, and HER2 had higher AR expression rate when compared with TNBC (P < 0.01) with no significant difference between the former 3 subtypes. Conclusion AR is widely expressed in breast cancer tissues. Compared with the TNBC, AR expression is higher in Luminal A, Luminal B and HER2 positive breast cancers. However, it is 44% in TNBC subtype. AR could serve as a potential therapeutic target to breast cancer.关键词
雄激素受体/乳腺癌/雌激素受体/孕激素受体/人表皮生长因子受体-2/细胞增殖核抗原Ki-67Key words
androgen receptor/breast cancer/estrogen receptor/progesterone receptor/human epidermal growth factor receptor-2/Ki-67分类
医药卫生
